

This spreadsheet is updated monthly and enables self-audit  
of a medicines formulary for adherence to current NICE Technology Appraisals.  
All guidelines refer to adults unless indicated.

ICB commissioned 2  
Non-ICB commissioned 4  
Not applicable 2  
ICB commissioned and approved 0 (%)  
Average days to compliance 0

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) [TA1052]</a>	Terminated appraisal	02/04/2025	TA					N/A	Terminated appraisal
<a href="#">Eftasoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over [TA1051]</a>	Recommended	02/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over [TA1054]</a>	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts / tertiary providers.	NHS England
<a href="#">Cladribine for treating active relapsing forms of multiple sclerosis [TA1053]</a>	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [TA1057]</a>	Recommended	16/04/2025	TA	15/07/2025	ICB			This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Proposed amber initiated RAG rating
<a href="#">Molnupiravir for treating COVID-19 [TA1056]</a>	Recommended	16/04/2025	TA	15/07/2025	ICB			This technology is commissioned by integrated care boards. Providers are Primary care providers and NHS hospital trusts.	Proposed red RAG rating
<a href="#">Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [TA1055]</a>	Recommended	16/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) [TA1058]</a>	Terminated appraisal	23/04/2025	TA					N/A	Terminated appraisal